To optimize drug concentration and improve outcomes, therapeutic drug monitoring is used to check the trough concentration and evaluate for the presence of anti-drug antibodies.
Clinical studies of Mytesi have shown that the most common adverse reactions were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough, and flatulence (3.1%).
Infliximab products work by neutralizing the biological activity of TNF-alpha by binding with high affinity to the soluble and transmembrane forms of TNF-alpha and inhibiting the binding of TNF-alpha with its receptors.
A recent opinion piece by Struyvenberg et al. aims to address the existing myths, remove the current confusion, and function as a practical guide to the diagnosis and treatment of EPI.
Overall, pancreatic exocrine insufficiency was identified in 10 patients (4.6%; 95% CI 2.2-8.3%) with five patients having severe pancreatic exocrine insufficiency (2.3%; 95% CI 0.8-5.3%).
Based on one retrospective review of 8 years of compliance, the strongest predictors of shorter length of stay were identified as no nasogastric tube, early mobilization, early oral nutrition, early removal of epidural and urinary catheter, and nonopioid analgesia.
The researchers found that there was no significant difference between the groups in terms of adverse events potentially related to abuse (2.8, 2.7, and 4.3%, respectively, for those given placebo, eluxadoline 75mg, or eluxadoline 100mg)
Individuals with a family history of CRC in a first-degree relative diagnosed before age 60 should undergo colonoscopy every 5 years beginning at age 40 or 10 years before the age at which their relative was diagnosed.
In 2 of the patients, some donor microbe strains persisted as long as 2 years after a transplant. In 5 others, donor strains persisted for 3 to 6 months, according to the University of Alabama at Birmingham researchers.
At Week 8, combined clinical and endoscopic remission was obtained in 13.0% of budesonide MMX patients vs. 7.5% of placebo patients.
Results showed that the endpoint was met with 27% in the tenapanor arm compared to 18.7% in the placebo arm (P=0.02) having at least 30% reduction in abdominal pain and an increase of 1 or more complete spontaneous bowel movements.
A total of 18.5% patients taking tofacitinib experienced a remission of their condition in 8 weeks compared to just 8.2% of patients receiving placebo.
Stable trends for a first-listed Crohn's disease diagnosis from 2003 to 2013 suggest that the previous annual increase has not continued.
The data showed no difference in the rates of adequate vaccine response between the 4 study groups (P=0.11). Patients with IBD taking immunosuppressive therapy did not differ from those not taking immunosuppressive therapy (90.6% vs. 88.2%; P=0.37).
Feagan, BG et al. "Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study"
The researchers found that the use of antibiotics within the previous 4 years wasn't associated with a heightened risk of colorectal adenomas, but long-term use in the past was.
The new application for an IBS-C indication is supported by data from two placebo-controlled Phase 3 studies that lasted 12 weeks and evaluated plecanatide in 2,100 patients with IBS-C.
The patient, a 33-year old woman with a history of drug hypersensitivity to NSAIDs and aspirin, presented for management of her chronic UC with mesalamine.
Since its approval in May 2015 through February 2017, the FDA has received 120 reports of serious cases of pancreatitis or death.
In this study, researchers aimed to determine how effective these pharmacological interventions are in school-aged children with recurrent abdominal pain (RAP).
Among randomized patients who entered the long-term extension trial period , 79.2% of patients receiving ustekinumab every 12 weeks and 87.1% of patients receiving ustekinumab every 8 weeks were in remission,
A fecal microbiota transplant through colonoscopy appears to be safe for recurrent Clostridium difficile infection during pregnancy, according to a case report published in the March issue of Obstetrics and Gynecology.
Implementation of a bundle of five items can reduce the surgical site infection (SSI) rate in colon surgery, according to a study published online February 1 in the Journal of Evaluation in Clinical Practice.
For patients with ulcerative colitis (UC) being treated with aminosalicylates, high dietary intake of certain fatty acids may increase the risk of flare.